Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Symptom overlap in anxiety and multiple sclerosis.
The microglial sensome revealed by direct RNA sequencing.
Treatment of human spasticity with delta 9-tetrahydrocannabinol.
Role of statins in the treatment of multiple sclerosis.
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?
Decreased Frontal Lobe Gray Matter Perfusion in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis Detected by the Bookend Technique.
CCSVI and MS: no meaning, no fact.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
An Empirical Investigation of a Biopsychosocial Model of Pain in Multiple Sclerosis.
Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis.
Painful Tonic Spasm in Neuromyelitis Optica: Incidence, Diagnostic Utility, and Clinical Characteristics.
Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Ongoing Oxidative Stress Causes Subclinical Neuronal Dysfunction in the Recovery Phase of EAE.
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.
Psychological effects of calisthenic exercises on neuroinflammatory and rheumatic diseases.

Pages